Westfield Capital Management CO LP Prothena Corp Public LTD CO Transaction History

Westfield Capital Management CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$10.99 - $44.21 $3.4 Million - $13.7 Million	-309,819 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$27.95 - $45.04 $10.4 Million - $16.7 Million	-370,840 Reduced 54.48%	309,819 $11.4 Million
Q4 2017 Feb 13, 2018	BUY	$35.44 - $63.76 $2.03 Million - $3.65 Million	57,170 Added 9.17%	680,659 $25.5 Million
Q3 2017 Nov 13, 2017	BUY	$53.83 - $67.75 $33.6 Million - $42.2 Million	623,489	623,489 $40.4 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.